A Win for Science, with Profound Implications for Industry: FDA Rejects MDMA
Mad in America
AUGUST 14, 2024
By late 2023, the general public perception was of two strong phase 3 trials that demonstrated the treatment’s efficacy in healing those with PTSD. Or perhaps the rejection of Lykos’ drug reveals something else: the powerful influence of the traditional pharmaceutical lobby at the cost of the upstart psychedelic industry.
133 
Let's personalize your content